Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5190669 | 0.93 | HPGD (0.51) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL5192017 | 0.88 | GPR119 (0.48) | HPGDKDM4EPKMGPR119 | |
| SCHEMBL5190677 | 0.84 | MEN1 (0.47) | HPGD | |
| SCHEMBL20656863 | 0.84 | HPGD (0.49) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL5190671 | 0.82 | KDM4E (0.52) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL27417726 | 0.82 | HPGD (0.50) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL15488486 | 0.82 | HPGD (0.47) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL6935422 | 0.82 | HPGD (0.47) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL4105386 | 0.81 | HPGD (0.49) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL3591623 | 0.81 | HPGD (0.54) | HPGDKDM4EPKMGPR119RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507760-B1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA AS (DK) | 2007-08-01 | — | — | EP | claimed |
| US-20050215588-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2005-09-29 | — | — | US | claimed |
| US-20070249676-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2007-10-25 | — | — | US | disclosed |
| US-7253193-B2 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2007-08-07 | — | — | US | disclosed |
| EP-1507760-B1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA AS (DK) | 2007-08-01 | — | — | EP | disclosed |
| US-20050215588-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249676-A1 | Cyanoguanidine prodrugs | CCNT1, CCND2, CCNT2 | HPGD 115/4885KDM4E 2664/4885PKM 1258/4885 |
| US-20050215588-A1 | Cyanoguanidine prodrugs | CCNT1, CCND2, CCNT2 | HPGD 115/4885KDM4E 2664/4885PKM 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.